Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Aim(s): The aim of this study was to explore the potential utility of PFS as a surrogate endpoint for overall survival (OS).
Materials and methods: We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE) and The Christie NHS Foundation Trust (Manchester). Patient eligibility criteria included GEP-NET primary, Ki-67 of 20% or less, and first-line somatostatin analogue (SSA) monotherapy for unresectable advanced disease. Correlation between PFS & OS was assessed by means of Kendall’s τ associated with Clayton’s copula models for bivariate survival data.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jimenez Fonseca P
To read the full abstract, please log into your ENETS Member account.